Dogbey D, Barth S
Mol Biotechnol. 2025; .
PMID: 39881109
DOI: 10.1007/s12033-025-01381-0.
Sandoval-Villegas N, Ivics Z
Mol Ther. 2024; 32(10):3211-3214.
PMID: 39326408
PMC: 11489527.
DOI: 10.1016/j.ymthe.2024.09.002.
Suoranta T, Laham-Karam N, Yla-Herttuala S
Front Mol Med. 2024; 2:1054069.
PMID: 39086961
PMC: 11285686.
DOI: 10.3389/fmmed.2022.1054069.
Nicolai C, Parker M, Qin J, Tang W, Ulrich-Lewis J, Gottschalk R
Blood. 2024; 144(9):977-987.
PMID: 38861668
PMC: 11406189.
DOI: 10.1182/blood.2024024523.
Jahandar-Lashaki S, Farajnia S, Faraji-Barhagh A, Hosseini Z, Bakhtiyari N, Rahbarnia L
Mol Biotechnol. 2024; .
PMID: 38822912
DOI: 10.1007/s12033-024-01195-6.
In vivo human T cell engineering with enveloped delivery vehicles.
Hamilton J, Chen E, Perez B, Sandoval Espinoza C, Kang M, Trinidad M
Nat Biotechnol. 2024; 42(11):1684-1692.
PMID: 38212493
PMC: 11236958.
DOI: 10.1038/s41587-023-02085-z.
AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery.
Theuerkauf S, Herrera-Carrillo E, John F, Zinser L, Molina M, Riechert V
Biomaterials. 2023; 303:122399.
PMID: 37992599
PMC: 10721713.
DOI: 10.1016/j.biomaterials.2023.122399.
Skeletal muscle-directed gene therapy: hijacking the fusogenic properties of muscle cells.
Buning H, Morgan M, Schambach A
Signal Transduct Target Ther. 2023; 8(1):340.
PMID: 37699901
PMC: 10497515.
DOI: 10.1038/s41392-023-01584-4.
CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes.
Kapitza L, Ho N, Kerzel T, Frank A, Thalheimer F, Jamali A
Front Immunol. 2023; 14:1183698.
PMID: 37646032
PMC: 10461316.
DOI: 10.3389/fimmu.2023.1183698.
Gene Therapy for Regenerative Medicine.
Hosseinkhani H, Domb A, Sharifzadeh G, Nahum V
Pharmaceutics. 2023; 15(3).
PMID: 36986717
PMC: 10057434.
DOI: 10.3390/pharmaceutics15030856.
Cell and gene therapy for kidney disease.
Peek J, Wilson M
Nat Rev Nephrol. 2023; 19(7):451-462.
PMID: 36973494
PMC: 10339687.
DOI: 10.1038/s41581-023-00702-3.
Vaccine Formulation Strategies and Challenges Involved in RNA Delivery for Modulating Biomarkers of Cardiovascular Diseases: A Race from Laboratory to Market.
Shaharyar M, Bhowmik R, Al-Abbasi F, Alghamdi S, Alghamdi A, Sarkar A
Vaccines (Basel). 2023; 11(2).
PMID: 36851119
PMC: 9963957.
DOI: 10.3390/vaccines11020241.
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F, Esmaeil N, Abbaspour M
Cancer Commun (Lond). 2022; 43(2):177-213.
PMID: 36585761
PMC: 9926962.
DOI: 10.1002/cac2.12394.
Engineered cell entry links receptor biology with single-cell genomics.
Yu B, Shi Q, Belk J, Yost K, Parker K, Li R
Cell. 2022; 185(26):4904-4920.e22.
PMID: 36516854
PMC: 9789208.
DOI: 10.1016/j.cell.2022.11.016.
Designed Ankyrin Repeat Proteins: A New Class of Viral Entry Inhibitors.
Walser M, Mayor J, Rothenberger S
Viruses. 2022; 14(10).
PMID: 36298797
PMC: 9611651.
DOI: 10.3390/v14102242.
siRNA Transfection Mediated by Chitosan Microparticles for the Treatment of HIV-1 Infection of Human Cell Lines.
Chronopoulou L, Falasca F, Di Fonzo F, Turriziani O, Palocci C
Materials (Basel). 2022; 15(15).
PMID: 35955275
PMC: 9369812.
DOI: 10.3390/ma15155340.
Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.
Michels A, Ho N, Buchholz C
Mol Ther. 2022; 30(7):2401-2415.
PMID: 35598048
PMC: 9263322.
DOI: 10.1016/j.ymthe.2022.05.018.
Gene-Modified Stem Cells for Spinal Cord Injury: a Promising Better Alternative Therapy.
Feng Y, Li Y, Shen P, Wang B
Stem Cell Rev Rep. 2022; 18(8):2662-2682.
PMID: 35587330
DOI: 10.1007/s12015-022-10387-z.
Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR-Cas9 into target cells.
Baron Y, Sens J, Lange L, Nassauer L, Klatt D, Hoffmann D
Mol Ther Nucleic Acids. 2022; 27:810-823.
PMID: 35141043
PMC: 8801357.
DOI: 10.1016/j.omtn.2021.12.033.
Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8.
Michels A, Frank A, Gunther D, Mataei M, Borner K, Grimm D
Mol Ther Methods Clin Dev. 2021; 23:334-347.
PMID: 34729380
PMC: 8531454.
DOI: 10.1016/j.omtm.2021.09.014.